Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 487.46 Million USD | -40.28% |
| 2022 | 816.3 Million USD | -6.53% |
| 2021 | 873.3 Million USD | 15.02% |
| 2020 | 759.24 Million USD | 34.41% |
| 2019 | 564.85 Million USD | 7.63% |
| 2018 | 524.78 Million USD | 234.29% |
| 2017 | 156.98 Million USD | 33.25% |
| 2016 | 117.81 Million USD | 68.65% |
| 2015 | 69.85 Million USD | 5.59% |
| 2014 | 66.15 Million USD | -14.67% |
| 2013 | 77.53 Million USD | 112.89% |
| 2012 | 36.41 Million USD | -17.77% |
| 2011 | 44.28 Million USD | -51.51% |
| 2010 | 91.32 Million USD | 6.13% |
| 2009 | 86.05 Million USD | 2.59% |
| 2008 | 83.88 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 374.92 Million USD | -23.09% |
| 2024 Q3 | 335.55 Million USD | -6.37% |
| 2024 Q2 | 358.37 Million USD | -4.41% |
| 2023 FY | 487.46 Million USD | -40.28% |
| 2023 Q1 | 879.65 Million USD | 7.76% |
| 2023 Q3 | 372.96 Million USD | -0.06% |
| 2023 Q2 | 373.19 Million USD | -57.58% |
| 2023 Q4 | 487.46 Million USD | 30.7% |
| 2022 Q3 | 840.33 Million USD | -1.55% |
| 2022 FY | 816.3 Million USD | -6.53% |
| 2022 Q1 | 811.07 Million USD | -7.13% |
| 2022 Q2 | 853.53 Million USD | 5.24% |
| 2022 Q4 | 816.3 Million USD | -2.86% |
| 2021 FY | 873.3 Million USD | 15.02% |
| 2021 Q3 | 744.57 Million USD | -5.45% |
| 2021 Q2 | 787.48 Million USD | 4.58% |
| 2021 Q1 | 752.99 Million USD | -0.82% |
| 2021 Q4 | 873.3 Million USD | 17.29% |
| 2020 Q3 | 801.14 Million USD | -2.9% |
| 2020 FY | 759.24 Million USD | 34.41% |
| 2020 Q1 | 576.48 Million USD | 2.06% |
| 2020 Q2 | 825.04 Million USD | 43.12% |
| 2020 Q4 | 759.24 Million USD | -5.23% |
| 2019 Q2 | 540.77 Million USD | -0.85% |
| 2019 Q1 | 545.43 Million USD | 3.93% |
| 2019 Q3 | 549.65 Million USD | 1.64% |
| 2019 FY | 564.85 Million USD | 7.63% |
| 2019 Q4 | 564.85 Million USD | 2.77% |
| 2018 Q4 | 524.78 Million USD | 4.84% |
| 2018 Q3 | 500.57 Million USD | 8.28% |
| 2018 FY | 524.78 Million USD | 234.29% |
| 2018 Q2 | 462.3 Million USD | -2.32% |
| 2018 Q1 | 473.29 Million USD | 201.49% |
| 2017 Q4 | 156.98 Million USD | 17.31% |
| 2017 Q3 | 133.81 Million USD | 14.4% |
| 2017 Q2 | 116.97 Million USD | 0.67% |
| 2017 Q1 | 116.19 Million USD | -1.38% |
| 2017 FY | 156.98 Million USD | 33.25% |
| 2016 FY | 117.81 Million USD | 68.65% |
| 2016 Q1 | 66.33 Million USD | -5.04% |
| 2016 Q3 | 111.74 Million USD | 43.98% |
| 2016 Q4 | 117.81 Million USD | 5.43% |
| 2016 Q2 | 77.61 Million USD | 17.0% |
| 2015 Q1 | 45.05 Million USD | -31.9% |
| 2015 FY | 69.85 Million USD | 5.59% |
| 2015 Q4 | 69.85 Million USD | 21.84% |
| 2015 Q3 | 57.33 Million USD | 10.68% |
| 2015 Q2 | 51.8 Million USD | 14.98% |
| 2014 Q1 | 68.5 Million USD | -11.64% |
| 2014 FY | 66.15 Million USD | -14.67% |
| 2014 Q4 | 66.15 Million USD | 9.88% |
| 2014 Q3 | 60.2 Million USD | -1.01% |
| 2014 Q2 | 60.82 Million USD | -11.22% |
| 2013 Q3 | 111.31 Million USD | 15.85% |
| 2013 Q4 | 77.53 Million USD | -30.35% |
| 2013 Q1 | 37.78 Million USD | 3.76% |
| 2013 FY | 77.53 Million USD | 112.89% |
| 2013 Q2 | 96.08 Million USD | 154.26% |
| 2012 Q2 | 41.98 Million USD | -2.2% |
| 2012 Q3 | 42.38 Million USD | 0.95% |
| 2012 Q4 | 36.41 Million USD | -14.07% |
| 2012 FY | 36.41 Million USD | -17.77% |
| 2012 Q1 | 42.92 Million USD | -3.07% |
| 2011 FY | 44.28 Million USD | -51.51% |
| 2011 Q3 | 104.82 Million USD | 0.0% |
| 2011 Q4 | 44.28 Million USD | -57.75% |
| 2010 FY | 91.32 Million USD | 6.13% |
| 2010 Q4 | 91.32 Million USD | -2.24% |
| 2010 Q3 | 93.41 Million USD | 0.0% |
| 2009 FY | 86.05 Million USD | 2.59% |
| 2009 Q4 | 86.05 Million USD | 0.0% |
| 2008 FY | 83.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Theratechnologies Inc. | 98.63 Million USD | -394.187% |
| Harrow Health, Inc. | 241.75 Million USD | -101.636% |
| Dynavax Technologies Corporation | 375.02 Million USD | -29.981% |
| Biofrontera Inc. | 23.13 Million USD | -2006.664% |
| Cronos Group Inc. | 43.73 Million USD | -1014.551% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -5467.165% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 40.362% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -906.215% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -2223.663% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -828.211% |
| Radius Health, Inc. | 804.29 Million USD | 39.392% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -3444.055% |
| DURECT Corporation | 30.4 Million USD | -1503.174% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1045.781% |
| Safety Shot Inc | 3.89 Million USD | -12424.55% |
| Phibro Animal Health Corporation | 725.54 Million USD | 32.814% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -5200.442% |
| Alvotech | 1.88 Billion USD | 74.107% |
| Assertio Holdings, Inc. | 148.41 Million USD | -228.442% |
| Rockwell Medical, Inc. | 30.88 Million USD | -1478.463% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -7839.621% |
| Procaps Group S.A. | 462.06 Million USD | -5.496% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -256.146% |
| SCYNEXIS, Inc. | 55.45 Million USD | -779.1% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -439.352% |
| Viatris Inc. | 27.21 Billion USD | 98.209% |
| OptiNose, Inc. | 194.33 Million USD | -150.835% |
| SIGA Technologies, Inc. | 57.97 Million USD | -740.779% |
| Tilray Brands, Inc. | 892.11 Million USD | 45.359% |
| PetIQ, Inc. | 645.22 Million USD | 24.451% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -7839.621% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 52.182% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -12822.685% |
| Alimera Sciences, Inc. | 107.35 Million USD | -354.069% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 48.573% |
| Silver Spike Investment Corp. | 3 Million USD | -16095.627% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -25610.443% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -168.778% |
| Journey Medical Corporation | 56.49 Million USD | -762.778% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -2186.856% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1164.457% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -6837.959% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -121.775% |
| PainReform Ltd. | 2.69 Million USD | -18014.493% |
| Cosmos Health Inc. | 30.25 Million USD | -1511.307% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -181.14% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -3376.401% |
| Embecta Corp. | 2.03 Billion USD | 76.059% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -221965.764% |
| Talphera, Inc. | 6.29 Million USD | -7649.777% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 30.784% |
| Incannex Healthcare Limited | 5.83 Million USD | -8261.252% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -5641.231% |
| Shineco, Inc. | 47.6 Million USD | -924.042% |
| Procaps Group, S.A. | 462.06 Million USD | -5.496% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -3.347% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -197.405% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 41.639% |
| Alvotech | 1.88 Billion USD | 74.107% |
| Hempacco Co., Inc. | 18.82 Million USD | -2489.791% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -182.422% |
| Bright Green Corporation | 6.43 Million USD | -7471.502% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 26.231% |
| Kamada Ltd. | 109.96 Million USD | -343.274% |
| Indivior PLC | 1.95 Billion USD | 75.018% |
| Evoke Pharma, Inc. | 9.64 Million USD | -4952.413% |
| Flora Growth Corp. | 17.22 Million USD | -2730.455% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -5641.231% |
| Evolus, Inc. | 209.68 Million USD | -132.471% |
| HUTCHMED (China) Limited | 536.38 Million USD | 9.121% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 44.194% |
| Akanda Corp. | 12.66 Million USD | -3747.702% |